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Abstract The influence of advanced glycosylation end products 
(AGE) on endothelial cells was investigated. When human 
umbilical endothelial cells were cultured with AGE-bovine serum 
albumin, viable cell number as well as DNA synthesis was 
significantly stimulated, whereas prostacyclin production by the 
endothelial cells was decreased. Antisense oligodeoxyribonucleo- 
tides against mRNA coding for AGE receptor were found to 
reverse both the AGE-induced growth stimulation and the 
inhibition of prostacyclin production in endothelial cells. These 
results thus suggest that AGE ligand-receptor interactions in 
endothelial cells can promote angiogenesis and thrombogenesis, 
leading to the development of diabetic vascular complications. 
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1. Introduction 
Glucose and other reducing sugars can react non-enzyma- 
tically with the amino groups of proteins to form reversible 
Schiff bases and then Amadori products. These early glycosy- 
lation products undergo further reactions and rearrangements 
to become irreversible crossed-linked, fluorescent protein de- 
rivatives termed advanced glycosylation end products (AGE). 
AGE are known to accumulate in various tissues of diabetic 
subjects, and are implicated in the development of diabetic 
complications [1]. 
We have shown recently that AGE can retard the growth of 
vascular pericytes and exhibit an immediate toxicity to these 
microvascular constituents through interactions with their re- 
ceptors, and proposed a novel mechanism for pericyte loss, 
the earliest histopathological hallmark in diabetic retinopathy 
[2,3]. 
In this paper, we describe the effects of AGE on the growth 
and prostacyclin-producing ability of endothelial cells. A pos- 
sible participation of the endothelial AGE ligand-receptor 
system in the development and progression of diabetic angio- 
pathies is discussed. 
*Corresponding author. Fax: (81) (762) 34-4226. 
Abbreviations: AGE, advanced glycosylation end products; BSA, 
bovine serum albumin; PBS, phosphate-buffered saline; FBS, fetal 
bovine serum; 6-keto-PGFla, 6-keto-prostaglandin Faa; RAGE, 
receptor for AGE; RT-PCR, reverse transcription-polymerase chain 
reaction. 
2. Materials and methods 
2.1. Preparation of AGE 
AGE were prepared by incubating bovine serum albumin (BSA) 
(fraction V, fatty acid-free, low endotoxin; Boehringer Mannheim 
GmbH, Germany) with 500 mM glucose in phosphate-buffered saline 
(PBS) (10 mM, pH 7.4) at 37°C for 6 weeks under sterile conditions 
[2]. Unincorporated sugars were removed by dialysis against PBS. 
AGE-BSA were purified by heparin-Sepharose CL-4B (Pharmacia 
LKB, Uppsala, Sweden) column chromatography; separation of 
AGE-BSA from non-glycated BSA was confirmed by SDS-PAGE. 
The concentration of AGE-BSA was determined by the method of 
Bradford [4]. 
2.2. Cells 
Endothelial cells were obtained from human umbilical vein and 
maintained in Roswell Park Memorial Institute tissue culture medium 
1640/Medium 199 (1/1) (Life Technologies, Grand Island, NY, USA) 
supplemented with 15% fetal bovine serum (FBS) (ICN Biomedicals 
Inc., Costa Mesa, CA, USA), 100 ~tg/ml endothelial cell growth sup- 
plement (Collaborative Research, Bedford, USA) and 25 Ixg/ml hepar- 
in [5]. 
2.3. Determination f viable cell number 
Endothelial cells cultured for various time periods in the presence 
or absence of AGE were dislodged with trypsin, and counted by the 
dye exclusion method [6]. 
2.4. Measurement of [3 H]thymidine incorporation 
[ZH]thymidine incorporation was determined as described pre- 
viously [7]. Briefly, endothelial cells were seeded at a density of 
2×104 ceils per well of a Costar 24-well cluster dish and kept at 
37°C overnight. After cell attachment, AGE were added to the medi- 
um, and cells were incubated for 24 h. Then [3H]thymidine was added 
to a final concentration of 1 I.tCi/ml, and cells were further incubated 
for 4 h. After incubation, ceils were fixed with ice-cold 10% (w/v) 
trichloroacetic acid for 20 min, and the resultant acid-insoluble ma- 
terials were processed for liquid scintillation counting. 
2.5. Measurement of 6-keto-prostaglandin F1a (6-keto-PGFxa) 
6-keto-PGFla released into media was measured with an Amer- 
sham enzyme immunoassay s stem according to the supplier's recom- 
mendation. 
2.6. Assay with antisense oligodeoxyribonucleotides 
A phosphorothioate antisense complement of human receptor for 
AGE (RAGE) mRNA, and the corresponding sense oligodeoxyribo- 
nucleotide, were synthesized and purified as described previously [2]. 
Sequences of antisense and sense oligonucleotides were 5'-CAACTG- 
CTGTTCCGGCT-3' and 5'-AGCCGGAACAGCAGTTG-3', respec- 
tively, which corresponded to nucleotides 6-22 of human cDNA [8]. 
The oligonucleotides were added to the medium, with 0.05 mg/ml 
AGE-BSA, in which endothelial cells were grown. After 4 h, 
[3H]thymidine incorporation and 6-keto-PGFla production were as- 
sayed. 
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2. 7. Quantitative r verse transcription-polymerase chain reaction (RT- 
PCR) 
Total RNAs isolated from endothelial cells were analyzed by RT- 
PCR as described previously, using primers specific to the human 
RAGE mRNA [2]. Primer sequences for detecting [3-actin mRNA 
were as given in [7]. Southern blot analysis of the RT-PCR products 
was performed with respective 32P-end labelled probes [2,7]. Template 
amounts and cycle numbers for amplification were chosen in quanti- 
tative ranges, which were determined by plotting signal intensities as 
functions of template amounts and of cycle numbers [7]. Signal in- 
tensities of hybridized bands were measured by a Fujix BAS 1000 
image analyzer (Fuji Photo Film Co. Ltd., Hamamatsu, Japan). 
3. Resu l t s  
3.1. Effects of AGE on the growth of endothelial cells 
Endothelial cells from human umbilical vein were cultured 
in the presence or absence of AGE-BSA, and the viable cell 
number was determined at days 1, 2 and 3 after AGE addi- 
tion. As shown in Fig. 1A, the growth curve was found to be 
shifted upwards by the treatment with AGE-BSA. At 0.1 mg/ 
ml, the growth rate was about 2-fold higher than that of the 
untreated cells; the AGE-induced increase was statistically 
significant at days 2 and 3 at every concentration tested. 
AGE also significantly stimulated DNA synthesis in endothe- 
lial cells (Fig. 1B). Non-glycated BSA induced no change in 
either the cell number or DNA synthesis. 
3.2. Effects of AGE on the prostacyclin production 
We next tested whether AGE affect the ability of endothe- 
lial cells to produce prostacyclin, the key substance ndowing 
the endothelium with anti-thrombogenic a tivities. When as- 
sayed for its stable metabolite, 6-keto-PGFla, prostacyclin 
production by endothelial cells was significantly lowered by 
AGE-BSA (Fig. 2). At 0.05 mg/ml, the amount of 6-keto- 
PGFla released by endothelial cells was decreased to about 
half of the control value without AGE-BSA. 
(A )  
., 7 '  
O 
~6. 
,,.,1 
Z 
~4 '  Q 
o 
ID 
> 
2 
0 
(B)  
, ~_°2001 , 
* . ~ 
o I 
' I j -  I-- 
;I ~) 3 ~ 0' 0.01 " 0.05 " 
[ 
Day AGE-BSA 
(mg/ml) 
0.1 0.1 
I 
BSA 
(rng/ml) 
Fig. 1. Effects of AGE-BSA on viable cell number (A), and on 
DNA synthesis (B) in human umbilical vein endothelial cells. (A) 
Endothelial cells were grown in the presence of 0.01 (ll), 0.05 (e) or 
0.1 ([]) mg/ml AGE-BSA or 0.1 mg/ml non-glycated BSA (A), or in 
the absence of BSA (©). Culture period after the addition of AGE- 
BSA is indicated on the abscissa, and the viable cell number on the 
ordinate. Each point represents he mean + S.E.M. of 3 replicate x- 
periments. (B) Endothelial ceils were treated with 0.01, 0.05 or 0.1 
mg/ml AGE-BSA, or 0.1 mg/ml non-glycated BSA, or without them 
for 24 h. [3H]thymidine incorporation was determined as described 
under section 2 and related to the value for the control with no ad- 
ditives. Each column represents he mean + S.E.M. of 3 replicate x- 
periments. *P < 0.05, compared to both the control value without 
additives and that with non-glycated BSA (Student's t-test). 
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Fig. 2. Effects of AGE-BSA on 6-keto-PGFla production in human 
umbilical vein endothelial cells. Amounts of 6-keto-PGFla released 
by endothelial cells are indicated on the ordinate. Endothelial cells 
were treated with 0.01, 0.05 or 0.1 mg/ml AGE-BSA, or 0.1 mg/ml 
non-glycated BSA, or without them for 2.5 days. Each column re- 
presents the mean+S.E.M, of 9 replicate experiments. * and **, 
P < 0.05 and P < 0.01, respectively, compared to both the control 
value without additives and that with non-glycated BSA (Student's 
t-test). 
3.3. Reversal of the AGE actions on endothelial cells by anti- 
sense oligonucleotides against RAGE rnRNA 
As we and others have shown previously, endothelial cells 
possess a cell surface RAGE [2,8]. We then examined its func- 
tional role in the AGE effects on endothelial cells, by manip- 
ulating the expression of RAGE gene with antisense DNA. 
Septadecamer antisense oligodeoxyribonucleotides comple- 
mentary to human RAGE mRNA,  and the corresponding 
sense control, were administered to culture media, in which 
endothelial cells were grown. As shown in Fig. 3A and B, the 
antisense oligomers were found to significantly diminish both 
the AGE-induced increase in DNA synthesis and the inhibi- 
tion of prostacyclin production in endothelial cells; at 10 txM, 
complete reversals were obtained. Sense oligomers did not 
affect the AGE actions. 
Evidence that the antisense oligomers did inhibit the expres- 
sion of the RAGE gene was obtained. Quantitative RT-PCR 
analysis confirmed the presence of RAGE mRNA in endothe- 
lial cells, and revealed that the antisense DNA could reduce 
the content of the target mRNA to about one-half of that of 
untreated control when standardized with the signal intensity 
of [3-actin mRNA (Fig. 4). 
4. D iscuss ion  
The present study demonstrated for the first time that AGE 
stimulate the growth but inhibit the prostacyclin-producing 
ability of human endothelial cells. The maximal effect of 
AGE was noted at 0.05 rather than 0.1 mg/ml in both 
DNA synthesis and prostacyclin production, but the dose- 
response relationship in the two indices was a striking mir- 
ror-image (see Fig. 1B and 2). These effects could be reversed 
by antisense DNA against RAGE mRNA,  indicating that 
these AGE actions on endothelial cells are mediated by the 
ligand-receptor interaction. The antisense DNA-induced de- 
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crease in RAGE mRNA (Fig. 4) was probably through 
RNase H- and RNase H-like activity-driven degradation [9]. 
The inhibition of binding and transition of ribosomes on tar- 
get mRNA [10] would seem to help account for the antisense 
effects. Although the AGE-induced changes appeared to be 
modest, chronic exposure to AGE accumulated uring pro- 
longed hyperglycemic states may give rise to local deteriora- 
tion in the growth or function of the endothelium. Tezuka et 
al. reported that similar concentrations of AGE stimulated the 
migration and tube formation of human umbilical vein en- 
dothelial cells but did not affect their proliferation [11]. 
Although no explanation as to why the endothelial cell 
growth under AGE differed between the two studies is avail- 
able, the differences in the type of growth supplements em- 
ployed or in the AGE preparations may be responsible. 
The response of pericytes to AGE contrasts with that of 
endothelial cells. As we have shown previously [2], the growth 
of the former is decreased by the AGE ligand-receptor inter- 
action. That AGE can differentially influence the growth of 
these two microvascular constituents would seem to be of 
significance. First, an in vivo sequela would be angiogenesis 
in either case. Because pericytes have been shown to halt en- 
dothelial cell growth [5,12], the AGE-induced decrease in the 
pericyte number would relieve this restriction and allow the 
neighboring endothelial cells to grow unchecked. Second, the 
post-AGE receptor signalling events may diverge even be- 
tween vascular endothelial cells and pericytes. How the ligand 
binding leads to the stimulation or to the repression of repli- 
cation in the respective cell type is an important issue to be 
clarified. 
Thrombogenesis would be another sequela of the AGE ac- 
tion on either endothelial cells or pericytes. Endothelial cell 
production of prostacyclin was inhibited by AGE (Fig. 2); 
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Fig. 3. Effects of antisense oligonucleofides on the AGE-induced 
stimulation of DNA synthesis (A) and the inhibition of prostacyclin 
production (B) in endothelial cells. Endothelial cells were cultured 
with 0.05 mg/ml AGE in the presence or absence of either 2 gM or 
10 gM oligomer or with neither AGE-BSA nor oligomers. (A) The 
percentage of [3H]thymidine incorporation is indicated on the ordi- 
nate. (B) The amount of 6-keto-PGFla released by endothelial cells 
is indicated on the ordinate. Each column represents the mean va- 
lues of 6 (A) or 4 (B) replicate experiments. Bars show S.E.M. * 
and **, P < 0.1 and P < 0.05, respectively, compared to the values 
obtained in the presence of AGE alone (Student's t-test). C, control 
without additives; AGE, 0.05 mg/ml AGE-BSA; +$2, 0,05 mg/ml 
AGE-BSA plus 2 pM sense oligomers; +S10, 0.05 mg/ml AGE-BSA 
plus 10 gM sense oligomers; +AS2, 0.05 mg/ml AGE-BSA plus 2 
ktM antisense oligomers; +AS10, 0.05 mg/ml AGE-BSA plus 10 pM 
antisense oligomers. 
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Fig. 4. Quantitative RT-PCR analysis of RAGE mRNA. Total 
RNAs from endothelial cells cultured with or without oligonucleo- 
tides for 8 h, a time period equivalent to that for the determination 
of DNA synthesis, were analyzed by RT-PCR; 100 ng of each 
RNA template was reverse-transcribed and amplified at 35 cycles 
where the reactions proceeded exponentially. Arrow indicates the 
position of the RT-PCR products (286 base pairs). C, control with- 
out oligomers; S, 10 laM sense oligomers; AS, 10 ktM antisense oli- 
gomers. Size markers (base pairs) are shown on the left. Lower 
panel shows signals derived from ~-actin mRNA. RT for the latter 
was performed with 100 ng of RNA templates, and the PCR ampli- 
fication was at 30 cycles. 
and, because pericyte-endothelial cell interactions are required 
to preserve the endothelial ability to synthesize prostacyclin 
[5], the AGE-induced growth retardation as well as their im- 
mediate toxicity in pericytes [2] should indirectly result in a 
focal decrease in the production of this anti-thrombogenic 
prostanoid. In addition, Esposito et al. [13] have shown that 
AGE can suppress the endothelial cell surface activity of the 
anti-coagulant factor thrombomodulin, and can induce the 
expression of procoagulant cofactor tissue factor, the conse- 
quences of both of which are again thrombogenesis. 
In conclusion, the available vidence suggests that AGE can 
drive endothelial cells to proliferate and to become thrombo- 
genic on one hand, and can damage pericytes on the other, 
leading to their dropout, which would in turn impair pericyte- 
endothelial interactions, further exacerbating endothelial dys- 
function. AGE may thus promote angiogenesis and thrombo- 
genesis, thereby playing an active part in the development and 
progression of diabetic angiopathy. 
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